UroGen Pharma Ltd.

URGN | $14.345 -1.27% 24K

(0.0% 1d) (-12.8% 1m) (25.2% 1y) (0.0% 2d) (1.1% 3d) (1.4% 7d) (-22.19% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 489,481,338
http://www.urogen.com
Sec Filling | Patents | 173 employees

(IL) UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. It has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. The firm's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's approved product, Jelmyto (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

hydrogen cancer treatment profitable

add to watch list Paper trade email alert is off

Press-releases

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
Published: 2024-04-17 (Crawled : 00:00) - biospace.com/
URGN | $14.345 -1.27% 24K

Health Technology

| 0.28% | O: 1.1% H: 0.0% C: 0.0%
association for meeting benefits

UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
URGN | $14.345 -1.27% 24K

Health Technology

| -3.77% | O: 1.46% H: 1.17% C: -1.44%
ugn-103 fda drug bladder cancer for application

UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
URGN | $14.345 -1.27% 24K

Health Technology

| 3.12% | O: -0.64% H: 0.71% C: -2.43%
pharma patent pharmaceuticals teva

A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors
Published: 2024-03-25 (Crawled : 13:30) - biospace.com/
URGN | $14.345 -1.27% 24K

Health Technology

| -7.8% | O: 2.73% H: 12.6% C: 2.9%
ALKS | $24.54 1.15% 260K

Health Technology

| -11.1% | O: 0.29% H: 0.71% C: -0.22%

UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
Published: 2024-03-14 (Crawled : 13:00) - biospace.com/
URGN | $14.345 -1.27% 24K

Health Technology

| -16.83% | O: -4.01% H: 0.69% C: -14.55%
ugn-102 jelmyto pharma company growth submission

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 8, 2024
Published: 2024-03-08 (Crawled : 14:00) - biospace.com/
URGN | $14.345 -1.27% 24K

Health Technology

| -19.41% | O: 0.33% H: 2.93% C: -0.55%
pharma nasdaq grants

UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
Published: 2024-03-04 (Crawled : 13:30) - biospace.com/
URGN | $14.345 -1.27% 24K

Health Technology

| -18.23% | O: 0.73% H: 4.08% C: 2.91%
pharma report financial results

UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
Published: 2024-02-26 (Crawled : 16:00) - biospace.com/
URGN | $14.345 -1.27% 24K

Health Technology